A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).
Mohammad Atiq(Memorial Sloan Kettering Cancer Center), Ravi A. Madan(National Cancer Institute), Lisa M. Cordes(National Institutes of Health Clinical Center), Amy Hankin(National Institutes of Health), Fatima Karzai(National Institutes of Health), James L. Gulley(National Cancer Institute), Megan Hausler(National Institutes of Health), William D. Figg(National Cancer Institute), Liza Lindenberg(National Cancer Institute), Peter L. Choyke(National Cancer Institute), Esther Mena Gonzalez(National Cancer Institute), Monique Williams(National Institutes of Health), Barış Türkbey(National Institutes of Health)
Cited by 0
Related Papers
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
|Nature Genetics|1997|1.5k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
|Journal of Clinical Oncology|2014|714
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
|Cancer Immunology Research|2015|456